Regulus rises on HCV data

Regulus Therapeutics Inc. (NASDAQ:RGLS) gained $1.21 (19%) to $7.49 on Wednesday after reporting interim data from a Phase II trial of a four-week regimen of RG-101 plus a once-daily direct-acting antiviral (DAA) to treat chronic HCV genotype 1 or 4 infection in treatment-naive patients.

In the study, 37 of 38 evaluable patients achieved a high virologic response, defined as HCV viral load below the level of quantification, eight weeks after treatment concluded. On a conference call, VP of Clinical Development Michael Huang said the patient who did not achieve a high virologic response had HCV RNA viral levels just above the limit of quantification. ...